Cognitive changes with omega-3 polyunsaturated fatty acids in non-demented older adults with low omega-3 index
To investigate the changes in specific domains of cognitive function in older adults reporting subjective memory complaints with a low omega-3 index receiving omega 3 polyunsaturated fatty acid (n-3 PUFA) supplementation or placebo.
This is a secondary exploratory analysis of the Multidomain Alzheimer Preventive Trial (MAPT) using subjects randomized to the n-3 PUFA supplementation or placebo group.
French community dwellers aged 70 or over reporting subjective memory complaints, but free from clinical dementia.
A subgroup of MAPT subjects in the lowest quartile of omega-3 index distribution with baseline values ≤ 4.83 % (n = 183).
The n-3 PUFA supplementation group consumed a daily dose of DHA (800 mg) and EPA (a maximum amount of 225 mg) for 3 years. The placebo group received identical capsules comprising liquid paraffin oil.
Linear mixed-model repeated-measures analyses were used including baseline, 6, 12, 24 and 36-month follow-up data to assess between-group differences in the change in eight cognitive tests over 36 months.
There was less decline on the Controlled Oral Word Association Test (COWAT) in the n-3 PUFA supplementation group compared to placebo (p = 0.009; between group mean difference over 36 months, 2.3; 95% CI, 0.6,4.0). No significant differences for any of the other cognitive tests were found, including other tests of executive functioning, although, numerically all results were in favour of the n-3 PUFA supplementation.
We found some evidence that n-3 PUFAs might be beneficial for the maintenance of executive functioning in older adults at risk of dementia with low omega-3 index, but this exploratory finding requires further confirmation. A larger specifically designed randomised controlled trial could be merited.
Key wordsOmega 3 polyunsaturated fatty acids executive functioning cognition
clinical dementia rating
clinical dementia rating sum of boxes
Controlled Oral Word Association Test
Digit Symbol Substitution Test
Fatty acid methyl esters
Free and Cued Selective Reminding test
polyunsaturated fatty acids
Multidomain Alzheimer Preventive Trial
mild cognitive impairment
Mini Mental State Examination
randomised controlled trial
Trail Making Test
Wechsler Adult Intelligence Scale-Revised
- 4.Sinn N, Milte CM, Street SJ, Buckley JD, Coates AM, Petkov J, et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr. 2012;107(11):1682–93.CrossRefPubMedGoogle Scholar
- 6.Boespflug EL, McNamara RK, Eliassen JC, Schidler MD, Krikorian R. Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment. J Nutr Health Aging. 2016 Feb;20(2):161–9.Google Scholar
- 7.Hooper C., De Souto Barreto P., Pahor M., Weiner M., Vellas B. (2017) The relationship of omega 3 polyunsaturated fatty acids in red blood cell membranes with cognitive function and brain structure: A review focussed on Alzheimer’s disease. Journal of prevention of Alzheimer’s disease. (in press).Google Scholar
- 9.Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16(5): 377-389.CrossRefPubMedGoogle Scholar
- 18.Wechsler D. Wechsler adult intelligence scale-revised. N Y Psychol Corp, 1981.Google Scholar